Orforglipron Outperforms Oral Semaglutide in Phase III Diabetes Trial

Eli Lilly and Company has reported positive results from the Phase III ACHIEVE-3 trial evaluating orforglipron against oral semaglutide in adults with Type 2 Diabetes whose condition was inadequately controlled with metformin. The findings were published in The Lancet.

The 52-week, randomised open-label study enrolled 1,698 patients across several countries, including China, Japan, the United States, Mexico, and Argentina. Participants received either 12 mg or 36 mg of orforglipron or 7 mg or 14 mg of oral semaglutide daily.

Results showed that orforglipron achieved greater reductions in A1C levels and body weight compared with oral semaglutide. It also improved cardiovascular risk markers such as systolic blood pressure, triglycerides, and cholesterol levels.

Across the broader ACHIEVE Phase III programme, more than 6,000 patients have been enrolled. Lilly has already submitted regulatory applications in over 40 countries and plans a US filing later this year.

05-03-2026